Alkermes Cites IL-2 Differentiation As It Moves To Phase III, And Seeks A Partner

Company Touts Nemvaleukin At Investor Day

 
• By Alaric DeArment
  
Handshake of businessmen
Alkermes looks to keep parts of its nemvaleukin program in-house while also seeking a partner for its broader development. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

More from Scrip